nivolumab

Known as: NIVO 
A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
BACKGROUND Nivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
Review
2017
Review
2017
BACKGROUND Programmed death 1 (PD-1) programmed death-ligand 1 (PD-L1) inhibitors show significant clinical activity in non-small… (More)
  • figure 6
  • table 1
  • table 2
Is this relevant?
Review
2017
Review
2017
BACKGROUND Patients with metastatic urothelial carcinoma have a dismal prognosis and few treatment options after first-line… (More)
  • figure 1
  • table 2
  • table 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Nivolumab (a programmed death 1 [PD-1] checkpoint inhibitor) and ipilimumab (a cytotoxic T-lymphocyte-associated… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Patients with advanced squamous-cell non-small-cell lung cancer (NSCLC) who have disease progression during or after… (More)
  • table 1
  • table 1
  • figure 1
  • table 2
  • table 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated… (More)
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in… (More)
  • table 1
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND Preclinical studies suggest that Reed-Sternberg cells exploit the programmed death 1 (PD-1) pathway to evade immune… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2013
Highly Cited
2013
BACKGROUND In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?